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Abstract
IL-23 and Th17 cells are key players in tissue immunosurveillance and are implicated in human immune-mediated diseases.
Genome-wide association studies have shown that the IL23R R381Q gene variant protects against psoriasis, Crohn’s disease
and ankylosing spondylitis. We investigated the immunological consequences of the protective IL23R R381Q gene variant in
healthy donors. The IL23R R381Q gene variant had no major effect on Th17 cell differentiation as the frequency of
circulating Th17 cells was similar in carriers of the IL23R protective (A) and common (G) allele. Accordingly, Th17 cells
generated from A and G donors produced similar amounts of Th17 cytokines. However, IL-23-mediated Th17 cell effector
function was impaired, as Th17 cells from A allele carriers had significantly reduced IL-23-induced IL-17A production and
STAT3 phosphorylation compared to G allele carriers. Our functional analysis of a human disease-associated gene variant
demonstrates that IL23R R381Q exerts its protective effects through selective attenuation of IL-23-induced Th17 cell effector
function without interfering with Th17 differentiation, and highlights its importance in the protection against IL-23-induced
tissue pathologies.
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Introduction
Increasing understanding of the mechanisms underpinning
immune-mediated inflammatory diseases such as psoriasis,
Crohn’s disease (CD) and ankylosing spondylitis (AS) has
implicated a pivotal role for the IL-23/Th17 cells axis in their
pathogenesis [1,2,3,4].
IL-23 consists of the unique IL-23p19 subunit coupled with the
common IL-12p40 subunit (shared with IL-12) [5]. It is mainly
produced by activated myeloid cells, as well as epithelial and
endothelial cells, and signals through its heterodimeric IL-23R
complex [6]. This complex consists of the IL-23R subunit paired
with the IL-12Rb1 subunit shared with the IL-12R complex.
Binding of IL-23 to IL-23R complex leads to STAT3 phosphor-
ylation, and IL-23-dependent gene expression.
IL-23 is a key pro-inflammatory cytokine driving autoimmu-
nity in animal models and human diseases. In mice, lack of IL-23
makes them resistant to experimental models of arthritis and
multiple sclerosis (MS) [7,8]. We and others have shown that
selectively targeting IL-23 prevents auto-immune inflammation
in experimental models of MS [9], inflammatory bowel disease
[10,11] and in a clinically relevant psoriasis model [12]. In
humans, IL-23 is over-expressed in clinical samples of psoriasis
[13], CD [14] and AS [15] and an anti-IL-12/IL-23p40 mAb is
efficacious in treating psoriasis and CD [16,17]. IL-23 plays a
critical role in Th17 response and production of the lineage-
defining cytokine IL-17A [18,19,20]. Human Th17 cells express
the master transcription factor RORC and the surface markers
CCR6, IL-23R and CD161 and they differentiate in the presence
of TGF-b1 and at least one pro-inflammatory cytokine such as
IL-1b, IL-6, IL-21 and IL-23 [21,22]. In addition to IL-17A, IL-
17F and IL-26, Th17 cells produce cytokines shared with other
Th cell subsets such as IL-22 and IFN-c [23,24]. Th17 cells drive
autoimmunity in experimental models [7,25] and have been
identified in clinical samples of psoriasis [26] and CD [27].
Although not required for early stages of Th17 development, as
naı¨ve T cells express little or no IL-23R [6], IL-23/IL-23R
signalling plays a critical role in favouring terminal differentia-
tion, maintenance and pathogenicity of effector Th17 cells [28],
with IL-23 driving local Th17 effector response. In animal
models of intestinal inflammation IL-23 acts as a key tissue-
specific effector cytokine amplifying the inflammatory response
[10,11,29]. Intradermal injection of IL-23 results in skin
inflammation in mice [30] and delivery of exogenous IL-23 in
IL-23p19 KO mice restores susceptibility to autoimmune
diseases [8,28].
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Strong evidence for the importance of the IL-23/Th17 axis in
immune-mediated diseases has emerged from genetics studies.
One of the most robust genetic findings is the association of a
variant in the IL23R gene with CD [31], psoriasis [32,33] and AS
[34]. We and others have found that the frequency of a single-
nucleotide polymorphism (SNP) in the IL23R is significantly higher
among healthy controls than in patients, suggesting a protective
effect of the rare allele from immune-mediated chronic inflam-
mation. The associated SNP, consisting in a guanine (G) to
adenine (A) substitution at DNA level, results in an arginine (R)
to glutamine (Q) substitution in position 381 (R381Q) within
the cytoplasmic domain of the IL-23R. Although this genetic
association has been replicated, the functional consequences of
carrying the protective gene variant are yet to be determined. One
possibility is that the IL23R R381Q SNP protects from multiple
immune-mediated diseases by impairing IL-23-mediated Th17
responses.
In this study we provide a comprehensive functional character-
ization of the protective IL23R R381Q gene variant in healthy
donors. We found that the IL23R R381Q SNP had no major effect
on Th17 cell differentiation; however, IL-23-induced Th17 cell
effector function was impaired in protective allele carriers resulting
in significantly reduced IL-17A production and STAT3 phos-
phorylation. These results support a critical role for the IL-23/IL-
23R signaling in generating pathogenic Th17 response.
Materials and Methods
Ethics Statement
This study was approved by the institutional review board of
Guy’s Hospital (Guy’s Research Ethics Committee, Ethics
Committee Code: 06/Q0704/18) and conducted in accordance
with the Helsinki Declaration, with informed written consent
obtained from each volunteer.
Healthy volunteers and Genotyping
Healthy individuals of Western European descent were selected
on the exclusion of personal or family history of immune-mediated
disorders, and genotyped for the IL23R R381Q variant. The
typing of 176 individuals resulted in no subjects homozygous for
the rare A allele (AA), 30 heterozygous A (A group) and 146
homozygous for the common G allele (G group). We used 41
donors (14 males, 27 females; mean age 34 years, range 23–65
years) to perform our functional studies: 19 A and 22 G
individuals. Genomic DNA was extracted from peripheral blood
by using a commercially available kit (Macherey Nagel, Du¨ren,
Germany), according to manufacturers’ instructions. IL23R
R381Q SNP was genotyped as previously described [33].
CD4+ T cells and PBMCs isolation
CD4+ T cells (purity over 98%) were isolated from peripheral
blood by incubation with Rosette Sep Human CD4+T cells
enrichment cocktail (StemCells Technologies, Grenoble, France)
followed by centrifugation on a density gradient (Lymphoprep,
PAA, Pasching, Austria). PBMCs were purified by centrifugation
through Lymphoprep.
Flow Cytometry
For cellular surface staining the following antibodies and
secondary reagents were used in different combinations: biotiny-
lated goat anti-human IL-23R (BAF1400, R&D System, Minne-
apolis, MN) [12,19,35], Streptavidin-APC (BD Bioscience, San
Jose, CA), CD3-FITC (eBioscience, San Diego, CA), CD4 PE-
Texas Red (Invitrogen, Carlsbad, CA), CD45RO-FITC (Dako,
Glostrup, Denmark), CD45RO-Pacific Blue (BioLegend, San
Diego, CA), CCR6-PE (BD Bioscience), CD45RA-PE (Invitro-
gen), CD45RA-PE-Cy7 (eBioscience), plus matched isotypes as
controls. Cells were acquired on a BD FACSAria II (BD
Bioscience). Analysis of FACS data was performed by FlowJo
(TreeStar, Ashland,OR) software.
Intracellular cytokines staining
PBMCs were activated with PMA (50 ng/ml, Sigma, St.Louis,
MO) plus ionomycin (250 ng/ml, Calbiochem, Darmstadt,
Germany) in the presence of monensin (3 mM, Sigma) for 5 hours.
Cells were subsequently stained for surface markers, fixed and
permeabilized in Fix Buffer and Permeabilization Buffer
(eBioscience) according to manufacturers’ instructions and stained
with IL-17A-PE (eBioscience) or matching isotype control.
Generation of Th17 cells from naı¨ve CD4+ T cells
Highly purified CD4+CD45RA+CD45RO2 naı¨ve T cells were
obtained by negative selection of CD4+ T cells using magnetic
beads (Dynabeads Pan Mouse IgG, Invitrogen) and the following
purified antibodies against unwanted cells: CD8 (Invitrogen),
TCRc/d (BD Bioscience), CD19 (Diaclone, Besanc¸on, France),
CD16 (Diaclone), CD14 (Diaclone), CD33 (Invitrogen), CD56
(Diaclone), CD45RO (Invitrogen).
Purity of CD4+CD45RA+CD45RO2 naı¨ve T cells was checked
by FACS and considered acceptable if over 95%.
CD4+CD45RA+CD45RO2 T cells were then polarized to Th17
phenotype according to a published protocol [19] with some
modifications. Of note, TGF-b in our cell culture came from
human AB serum and upon checking by ELISA, using a
commercially available TGF-b ELISA kit (R&D Systems)
according to manufacturers’ instructions, resulted equal to
0.460.1 ng/ml, within the optimal range (0.1–1 ng/ml) reported
for Th17 polarization [20]. Briefly, cells were cultured at density of
56105 cells/ml in U-bottomed 96-well plates in RPMI medium
containing 10% human AB serum (Biowhittaker, Walkersville,
MD) (10% RPMI-hAB) along with anti-CD3/CD28 coated beads
(1 beads per cell, Dynabeads CD3/CD28 T cell Expander,
Invitrogen) and recombinant human IL-1b (50 ng/ml, Peprotech,
Rocky Hill, NJ), where required, for 6 days. On d6 cells were
counted and expanded for additional 7 d using IL-2 (100 UI/ml,
R&D Systems) and IL-1b in the presence or absence of IL-23
(50 ng/ml, R&D Systems). On d13 cells were counted, washed
and used for flow cytometry analysis, RNA extraction or further
re-stimulated as described below.
Th17 cell activation
To determine cytokine mRNA levels, IL-1b/IL-23 or IL-1b-
polarized cells on d13 of culture were left un-stimulated or
stimulated with IL-23 (10 ng/ml) for 24 h. Cells were stored in
TRIzol reagent (Invitrogen) at 280uC until further use.
Cells from each culture condition were either unstimulated or
stimulated with PMA (5 ng/ml) plus ionomycin (3 mg/ml), or IL-
23 (10 ng/ml), for 48 h to determine cytokine production. Cell–
free supernatant was collected and stored at 280uC until further
use.
RNA extraction and quantitative RT-PCR (qRT-PCR)
Total RNA was obtained using TRIzol according to the
manufacturers’ instructions and reverse transcribed into cDNA.
RORC, IL-23R, CCR6, IL-17A, IL-17F, IL-22 and IL-26
expression was assessed by multiplex real-time quantitative RT-
PCR using Taqman assays (Applied Biosystems, Carlsbad, CA)
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according to the manufacturers’ instructions. For each sample,
mRNA abundance was normalized to the amount of human
GAPDH. Data analysis was performed using the DDCt method:
results are expressed either as fold change or as relative mRNA
levels in arbitrary units.
Determination of IL-17A, IFN-c and IL-22 levels
IL-17A and IFN-c cytokine levels in the supernatants were
assayed using the Fluorokine MAP Human Base Kit A (R&D
Systems) and acquired on a Luminex 100 flow-based sorting and
detection analyzer (Luminex Corporation, Austin, TX).
IL-22 cytokine level was assayed using a commercially available
IL-22 ELISA kit (R&D Systems) according to manufacturers’
instructions.
pSTAT-3 intracellular staining
For determination of pSTAT-3 IL-1b-polarized cells were
rested for 24 h and either left un-stimulated or stimulated with IL-
23 (10 ng/ml) for 15 min. Cells were fixed, permeabilized and
stained with pSTAT3 (Tyr 705) (Cell Signaling, Danvers, MA) and
secondary goat anti-rabbit-Alexa 488 (Invitrogen), according to
the manufacturers’ instructions.
Statistical analysis
For flow cytometry experiments cell percentages and MFI
values obtained for each donor belonging to the two genetic
groups were assessed for normal Gaussian distribution with
D’Agostino & Pearson omnibus normality test and then analyzed
by unpaired two-tailed t test by using Prism version 4.0 (GraphPad
Software, La Jolla, CA). For cytokine secretion experiments cell
supernatants were assayed in duplicates, mean 6 SEM was
calculated, results were assessed for normal Gaussian distribution
and then analyzed by Mann-Whitney test. For mRNA expression
analysis qRT-PCR was performed in triplicates, mean 6 SD was
calculated, results were assessed for normal Gaussian distribution,
and then analyzed by Mann-Whitney, unpaired two-tailed t or
Wilcoxon signed rank test, as appropriate. Values of P,0.05 were
considered significant.
Results
Study of circulating Th17 cells in IL23R R381Q gene
variant carriers
As a first step to study the functional consequences of the IL23R
R381Q gene variant we chose an appropriate study population.
We studied a population of healthy donors rather than patients,
due to the possible presence of more confounding gene variants in
patients. Out of 176 individuals typed for the IL23R R381Q SNP,
30 individuals were heterozygous for the protective A allele (A
group) and 146 individuals homozygous for the common G allele
(G group). No subjects were homozygous for the very rare A allele
(AA), in keeping with its genotype frequency (less than 1% AA
homozygous in individuals of Western European descent,
HapMap project, public release #27). We ultimately used 19 A
and 22 G individuals for functional studies.
Given the clear link between IL-23 and Th17 cells, we
hypothesized that the IL23R R381Q SNP could affect IL-23/IL-
23R signalling, impairing Th17 responses.
To test our hypothesis we first studied freshly isolated PBMCs in
the absence of cell expansion or manipulation and investigated
whether there was any difference in circulating Th17 cells,
between the A and G group. Human Th17 cells were defined by
surface co-expression of IL-23R and CCR6 and by the production
of IL-17A in response to polyclonal stimulation, as, in keeping with
a published study [35], IL-23 stimulation was unable to
consistently induce a detectable IL-17A response in freshly isolated
memory Th cells from healthy donors (data not shown). As
previously shown [36], we observed individual variation within our
cohort of healthy donors, in both the percentage of circulating
Th17 cells and of IL-17A+ cells (Fig. 1A, B). Percentage of IL-
23R+CCR6+ Th17 cells within memory Th cells ranged from 3.42
to 22.90 (Fig. 1A). There was no significant difference neither in
the percentage of Th17 cells (Fig. 1A, Fig. S1A), nor in IL-23R
mRNA expression (Fig. S1B) or in the percentage of IL-23R+ cells
(Fig. S1C, D) and IL-23R Median Fluorescence Intensity (MFI)
(Fig. S1E, F) in purified Th cells between the A vs the G group.
The percentage of IL-17A+ cells within the memory Th cells
ranged from 0.01 to 2.68 (Fig. 1B, Fig. S1G). While there was a
slight reduction in percentage of IL-17A+ cells in the protected A
group, this did not reach statistical significance. Such subtle
differences, although not conclusively able to exclude impairment
in Th17 cells generation in protective A allele carriers, leave open
the possibility that environmental and/or immunological factors,
rather than the IL23R R381Q SNP, might have impacted on
Th17 cell development and function in our cohort. A similar
scenario, described also by others [36], highlights that the degree
of inter-individual variability in Th repertoire composition
provides a challenge when assessing functional consequences of
gene variants. To overcome such inter-individual variability, we
established a cell culture system for the generation of in vitro
polarized Th17 cells which enabled us to pinpoint subtle
Figure 1. IL23R R381Q gene variant and circulating Th17 cells. PBMCs from normal G (green squares) or protected A (red squares) donors
were stained for Th17 cell surface markers and for IL-17A production. (A) Percentage of IL-23R+CCR6+ Th17 cells and (B) of IL-17A+ cells, within
memory Th cells. Each symbol corresponds to one individual, horizontal bars represent means. Unpaired t test was performed yielding P values.0.05
for both panels.
doi:10.1371/journal.pone.0017160.g001
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functional impacts of the IL23R SNP and to discriminate between
IL-23 effect in Th17 differentiation and effector functions.
Effect of the IL-23R R381Q gene variant on IL-23-induced
Th17 cell differentiation
Although dispensable in the first stage of human Th17
differentiation, IL-23 is required to drive terminal differentiation
and maintenance of already committed Th17 cells [21]. To
investigate whether the IL23R R381Q SNP has an effect on IL-23-
induced Th17 differentiation, we generated Th17 cells with IL-1b,
in the presence of IL-23 added at d6 of culture during cell
differentiation (Fig. 2A). On d13/15 the cells showed phenotypic
and functional characteristics of fully differentiated effector Th17
cells. IL-1b/IL-23-polarized cells expressed higher mRNA levels
of RORC (P,0.001), IL-23R (P,0.001) and CCR6 (P,0.01),
(Fig. 2B) and produced significantly higher amounts of IL-17A
cytokine (P,0.01) and IL-17F and IL-26 mRNA (Fig. 2C and not
shown) compared to un-polarized control cells.
There was no difference between A and G group in the
percentage of IL-23R+CCR6+ Th17 cells (P.0.05, Fig. 3A) and
in mRNA levels of RORC, IL-23R and CCR6 (P.0.05, Fig. 3B).
IL-17A production at protein (IL-17A: G group med-
ian = 163 pg/ml, from 5 to 1612 pg/ml, n = 15 vs A group
median = 204 pg/ml, from 42 to 591, n = 9; P.0.05, Fig. 3C) and
mRNA level (IL-17A mRNA levels: G group median = 1.09, from
0.23 to 5.23, n = 15 vs A group median = 0.81, from 0.10 to 6.06,
n = 9; P.0.05, Fig. 3D) did not differ between the two groups.
Similarly there was no difference in IL-17F and IL-26 mRNA
(Fig. S2A, B) and in IL-22 production at both protein and mRNA
levels (Fig. S2C, D) between A and G group. Temporal analysis of
IL-23R expression showed no difference in the percentage of IL-
23R+ cells (Fig. S2E) and in IL-23R MFI (Fig. S2F) between A and
G group.
These results obtained with in vitro polarized Th17 cells in the
presence of IL-23 suggest that the IL23R R381Q SNP does not
affect human Th17 differentiation and are consistent with those
obtained with freshly isolated circulating Th17 cells.
IL-23R R381Q gene variant impairs Th17 effector function
Accumulating evidence suggests a pathogenic role for IL-23 in
inflamed epithelial tissues. We wondered if the IL23R R381Q SNP
would impair IL-23-induced Th17 effector function. To mimic
Th17 cell response in inflamed tissue we studied the effect of short-
term IL-23 stimulation on already committed Th17 cells at d13 of
culture (Fig. 4A). Phenotypic characterization of IL-1b-polarized
Th17 cells showed a higher mRNA expression of RORC
(P,0.01), IL-23R (P,0.001) and CCR6 (P,0.01) compared to
un-polarized control cells (Fig. 4B). When IL-1b-polarized cells
were polyclonally stimulated for a further 48 h they produced
statistically significant more IL-17A (P,0.01), IL-22, and IFN-c
cytokines as well as IL-17F and IL-26 mRNA (Fig. 4C and data
not shown) compared to non-polarized control cells.
Figure 2. IL-1b/IL-23-polarized cells express Th17 markers and produce IL-17A. (A) Naive CD4+ T cells were cultured for 6 d in the presence
of anti-CD3/CD28 coated beads, with or without IL-1b. On d6 cells were counted and IL-2 added to each condition, together with IL-1b and IL-23,
where required. IL-1b/IL-23-polarized Th17 cells were collected after 13 d of culture for phenotypic analysis or rested and assayed for Th17 cytokine
on d14/15. (B) mRNA expression levels of RORC, IL-23R and CCR6 on d13 were significantly increased in IL-1b/Il-23-polarized cells. (C) IL-17A
production on d15 was significantly enhanced in IL-1b/Il-23-polarized cells. Results are representative of 5 experiments. Each symbol corresponds to
one individual, horizontal bars represent medians. Wilcoxon signed rank test was performed. ** P,0.01, ***P,0.001.
doi:10.1371/journal.pone.0017160.g002
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We next assessed whether Th17 cells would respond to 48 h IL-
23-stimulation by producing IL-17A and other Th17 cytokines. As
shown in Fig. 4D, IL-17A production was significantly (P,0.05)
increased in IL-23-stimulated IL-1b-polarized Th17 cells com-
pared to unstimulated cells. In contrast, un-polarized control cells
did not respond to IL-23. IL-1b-polarized cells also expressed IL-
17F and IL-26 mRNA, as well as IL-22 and IFN-c in response to
IL-23 (data not shown).
Immunophenotypic analysis of IL-1b-polarized Th17 cells
revealed that the percentage of d13 CCR6+IL-23R+ Th17 cells
did not differ significantly between the two genetic groups (A vs G,
P.0.05) (Fig. 5A). This was also true for the relative mRNA levels
of RORC, IL-23R and CCR6 (A vs G, P.0.05) (Fig. 5B).
Similarly, temporal analysis of IL-23R expression showed no
difference in the percentage of IL-23R+ cells (Fig. S3A) and IL-
23R MFI (Fig. S3B) between A and G groups. The two genetic
groups showed also a similar up-regulation of IL-23R mRNA in
response to IL-23-stimulation for 48 h (Fig. S3C). Thus, IL-1b-
polarized Th17 cells represented a suitable tool to study the impact
of the IL23R R381Q SNP in IL-23-induced Th17 effector
response, as Th17 cells from A and G group were similar not
only numerically and phenotypically but also in their capacity to
respond to IL23 as they had transcriptionally up-regulated the IL-
23R at the same level.
When IL-1b-polarized Th17 cells were stimulated with IL-23
for 48 h we detected a statistically significant reduction in IL-23-
induced IL-17A net production in protective A allele carriers
compared to the group carrying only G alleles (G group
median = 36.0 pg/ml, from 0 to 238 pg/ml, n = 17 vs A group
median = 5.5 pg/ml, from 0 to 71 pg/ml, n = 14; P,0.01)
(Fig. 6A). We also found a significant reduction of IL-17A mRNA
in response to IL-23 in the Th17 cells from A versus G group (IL-
17A mRNA fold increase G group mean = 2.43, from 0.53 to 5.40,
n = 17 vs A group mean = 1.65, from 0.41 to 2.92, n = 14; P,0.05)
(Fig. 6B). These data suggest that the R381Q gene variant
negatively affects IL-23 signal transduction and ultimately IL17A
transcription. We tested the impact of the IL23R R381Q SNP on
IL-23 signalling, focusing on STAT3 phosphorylation (pSTAT3).
Figure 3. IL23R R381Q gene variant does not affect Th17 differentiation. IL-1b/IL-23-polarized Th17 cells were used for phenotypic analysis
(on d13) or assayed for IL-17A mRNA expression (on d14) or secretion (on d15). (A) Percentage of CCR6+IL-23R+ IL-1b/IL-23-polarized Th17 cells did
not significantly differ between G (green triangles) and A group (red triangles). (B) mRNA expression levels of RORC, IL-23R and CCR6 did not differ
between G and A group. (C) IL-17A production and (D) IL-17A mRNA expression did not differ between G and A group. Each symbol represents one
individual, horizontal bars represent medians. Mann Whitney test was performed yielding P values.0.05 for all panels.
doi:10.1371/journal.pone.0017160.g003
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To detect and quantify small differences in pSTAT3 at single cell
level [37] we performed phospho-flow cytometry analysis,
providing us with both a higher sensitivity and specificity than
conventional western blot analysis (data not shown). We found that
the magnitude of IL-23-induced pSTAT3 in Th17 cells (expressed
as fold MFI relative to unstimulated cells [37]) was significantly
reduced in the A vs G group (Fig. 6C, D). This reduction was
specific for IL-23R signalling as there was no variation in pSTAT3
between the A and G group when Th17 cells were stimulated with
the major pSTAT3-inducing cytokine IL-6 (Fig. S3D, E). IL-23
stimulation of Th17 cells from group A and G did not show a
statistically significant difference in cytokine production and
mRNA expression of pro-inflammatory cytokines (IL-17F, IL-22,
IL-26, IFN-c) (Fig. S3F-I).
Thus, we detected a significantly reduced production of IL-17A
as well as impaired STAT3 phosphorylation in Th17 effector cells
from carriers of the protective IL23R gene variant.
Discussion
In this study we provide the first functional characterization of
the IL23R R381Q SNP showing an impaired IL-23-induced Th17
response in carriers of the A protective allele. Using PBMCs from
healthy donors we detected no major difference in the number and
activity of circulating Th17 cells between G and A allele carriers.
In keeping with these results, Th17 cells generated in vitro from
naı¨ve T cells in the presence of IL-23 consistently showed a similar
phenotype and functional activity in both G and A group.
Figure 4. IL-1b-polarized cells express Th17 markers and produce IL-17A in response to IL-23. (A) Naı¨ve CD4+ T cells were cultured for
6 d in the presence of anti-CD3/CD28 coated-beads, with or without IL-1b. On d6 cells were counted and IL-2 added to each condition, together with
IL-1b, where required. IL-1b-polarized Th17 cells were collected after 13 d of culture for phenotypic analysis or assayed for Th17 cytokine on d14/15.
(B) mRNA expression levels of RORC, IL-23R and CCR6 on d13 were significantly increased in IL-1b-polarized cells. (C) IL-17A production in response to
PMA/Ionomycin (PMA) was significantly enhanced in IL-1b-polarized cells. (D) IL-1b-polarized cells produced higher level of IL-17A in response to IL-
23 than control cells. Results are representative of 5 experiments. Each symbol corresponds to one individual, horizontal bars represent medians.
Wilcoxon signed rank test was performed. *P,0.05, **P,0.01, ***P,0.001.
doi:10.1371/journal.pone.0017160.g004
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Figure 5. IL23R R381Q gene variant and IL-1b-polarized Th17 cells. IL-1b-polarized Th17 cells were used for phenotypic analysis on d13. (A)
Percentage of CCR6+IL-23R+ IL-1b-polarized cells did not significantly differ between G (green triangles) and A group (red triangles). (B) mRNA
expression levels of RORC, IL-23R and CCR6 did not differ between G and A group. Each symbol represents one individual donor; horizontal bars
represent medians (A) or means (B). Mann Whitney test (A) or unpaired t test (B) were performed yielding P values .0.05 for all panels.
doi:10.1371/journal.pone.0017160.g005
Figure 6. IL23R R381Q gene variant reduces IL-23-induced IL-17A production and STAT3 phosphorylation. IL-1b-polarized Th17 cells
collected on d13 were stimulated with IL-23. (A) IL-17A production in response to 48 h IL-23 stimulation was significantly reduced in IL-1b-polarized
Th17 cells from A (red dots) compared to G (green dots) group. Data are expressed as net IL-17A production in response to IL-23. (B) IL-17A mRNA
expression in response to 24 h IL-23 stimulation was significantly reduced in IL-1b-polarized Th17 cells from A compared to G group. Data are
expressed as fold increase compared to unstimulated cells. (C) Representative flow cytometry histograms from G (green frame) and A (red frame)
donors showing STAT-3 phosphorylation in response to 15 min IL-23-stimulation (blue line) as compared to unstimulated control cells (black line)
and expressed as fold Median Fluorescence Intensity (MFI). (D) STAT3 phosphorylation in response to IL-23-stimulation was reduced in IL-1b-
polarized cells from A compared to G group. Each symbol represents one individual donor; horizontal bars represent medians (A) or means (B, D).
Mann-Whitney (A) or unpaired t test (B, D) was performed, *P,0.05 **P,0.01.
doi:10.1371/journal.pone.0017160.g006
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However, effector Th17 cells from individuals carrying the
protective IL23R SNP produced significantly less IL-17A in
response to IL-23 and had impaired IL-23 signalling at the level
of pSTAT3.
The IL-23/Th17 axis has received considerable interest in the
past few years, as it is key both in protective immunity against
infections and pathogenic in some autoimmune-type diseases, such
as psoriasis, CD and AS. Tissue-derived IL-23 can drive
pathogenic Th17 effector responses leading to overwhelming
inflammation and autoimmunity. Genetic studies have shown that
the less common A allele of the IL23R confers approximately
threefold protection against developing CD [4] and twofold
protection against psoriasis [38] and AS [34].
In this study we used Caucasian healthy donors with no
personal or family history of psoriasis, CD or AS. We chose not to
investigate the effect of the IL23R R381Q SNP in patients as we
assumed that the protective effect of the IL23R variant might have
been partially overcome by other genetic or environmental factors
that contribute to disease pathogenesis. Due to the low frequency
of the genetic variant of interest (,1% AA homozygous in
individuals of Western European descent), which might be based
on a negative evolutionary selection of the A allele to preserve an
adequate Th17 response against infection, we only had access to
individuals that were heterozygous for the IL23R R381Q gene
variant.
A key finding of our study was that the protective IL23R SNP
affects IL-23 signalling in Th17 effector cells impairing IL-17A
production without interfering with the differentiation of Th17 cells
from naı¨ve T cells. In fact, the number and activity of both
circulating Th17 cells and in vitro differentiated Th17 cells did not
differ between G and A allele carriers. This finding supports the
current concept of a major role for IL-23 in the generation of
Th17 cell effector response in tissue inflammation, rather than in
systemic inflammation and demonstrates the importance of IL-23
in mediating Th17 effector response in humans. Our results
suggest a protective effect of the IL23R R381Q SNP in IL-23-
mediated IL-17A-induced peripheral tissue pathology seen in
chronic inflammatory diseases (Fig. 7).
IL-23 signalling impairment only affected IL-17A production
and not the other cytokines produced by Th17 cells. It has been
shown that cultured Th17 cells are heterogeneous in their cytokine
production with some producing solely the lineage–defining
cytokine IL-17A and others secreting combinations of other Th-
17 related cytokines, e.g. IL-22 and IFN-c [23,24]. Therefore, our
Figure 7. Importance of IL-23 and IL23R R381Q gene variant in Th17 cell immunobiology. The IL-23/IL-23R axis is believed to play a role in
both Th17 differentiation in the lymph node and Th17 cell effector functions in peripheral tissues, with the latter becoming increasingly relevant,
especially in the context of IL-23-induced tissue pathologies, like psoriasis and Crohn’s disease. Our data about the functional consequences of
carrying the protective A allele of the IL23R R381Q gene variant suggest that its protective effect against autoimmune disease is driven trough
impairment of Th17 cell effector functions, i.e. IL-17A production, rather than Th17 differentiation.
doi:10.1371/journal.pone.0017160.g007
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findings raise the possibility that the IL23R R381Q SNP mainly
exerts its effect on cells producing only IL-17A, while preserving
an adequate overall cytokine response.
By demonstrating the immunological consequences of the
protective IL23R R381Q SNP we have provided further insight
into the role of the IL-23/Th17 axis in immune-mediated diseases.
Our study is one of the first to demonstrate that functional
characterization of gene variants associated with human common
complex diseases is feasible. The overall magnitude of a given gene
variant to protect against disease might be small, but, as in the case
of the IL23R gene variant, there are compelling scenarios
contributing to disease pathogenesis. The positive outcome of
our immunogenetic study suggests that parameters such as
adequate study population, sufficient statistical power, relevant
cell type and pertinent biological read out are critical in
discovering the functional impact of disease-associated SNPs. A
study using human T cell blasts transduced with the two IL23R
variants was unable to detect any differences in IL-23-induced
STAT phosphorylation and IFN-c and IL-10 production [39].
This finding was confirmed using mouse Ba/F3 cells infected with
IL23R gene variants (E. Oldham and R. Kastelein, personal
communication). In our study we used a more physiological model
system using primary human cells from typed individuals without
the need for genetic manipulation. In addition, we specifically
looked at the effect of IL23R R381Q SNP in Th17 cells, using IL-
17A as read out for Th17 cell effector function.
Finally, our results are relevant in the context of the clinical
efficacy of mAbs targeting IL-12/IL-23p40 in psoriasis and CD
[16,40]. Studies are currently ongoing to investigate whether the
protective IL23R gene variant might also contribute to a different
disease phenotype in psoriasis, as it has been suggested in CD
patients [41]. It is also feasible that the IL23R SNP could be used
as a novel biomarker to predict therapeutic response and studies
are currently ongoing to test this hypothesis in psoriasis. Thus,
insights gleaned from ‘‘gene to function’’ studies could be
translated into designing more efficient and cost-effective clinical
trials for immune-targeted drug therapy in chronic inflammatory
diseases.
Supporting Information
Figure S1 Effect of IL23R R381Q gene variant on
circulating Th17 cells and IL-23R protein and mRNA
expression. Circulating Th17 cells were analysed in PBMCs.
Representative flow cytometry contour plots showing (A) percent-
age of IL23R+CCR6+ Th17 cells within CD3+CD4+CD45RO+
cells in G (green frame) and A (red frame) donors. Isotype controls
are shown. IL-23R expression was analyzed in purified total CD4+
T cells by flow cytometry and qRT-PCR. (B) mRNA expression
level of IL-23R in total CD4+ T cells in G (green squares) or A (red
squares) donors. (C) Representative flow cytometry contour plots
showing percentage of IL23R+ cells within purified CD4+ T cells
in G and A donors. Isotype controls are shown. (D) Percentage of
total CD4+ T cells expressing IL-23R in G or A donors. (E)
Representative flow cytometry histogram showing median fluo-
rescence intensity (MFI) as measurement of IL-23R expression in a
G (green line) and an A (red line) donor. Isotype control is shown
(tinted grey) (F) CD4+IL-23R+ T cells MFI in G (green) or A (red)
healthy individuals. (G) Representative flow cytometry contour
plots showing percentage of CD45RO+IL17+ cells within
CD3+CD4+cells determined for G and A donors by intracellular
cytokine staining. Isotype controls are shown Each symbol in
panels B, D and F corresponds to a value obtained from an
individual and horizontal bars represent means. Unpaired t test
was performed yielding P values .0.05 for all panels.
(TIF)
Figure S2 Effect of IL23R R381Q gene variant on
Th17cell differentiation. IL-1b/IL-23 polarized Th17 cells
were collected after 13d of culture, rested and then assayed for
mRNA expression (on d14) or Th17 cytokine secretion (on d15).
IL-17F (A) and IL-26 (B) mRNA and IL-22 protein secretion (C)
and mRNA expression (D) in IL-1b/IL-23 polarized Th17 cells
did not differ between G (green triangles) and A (red triangles)
group. Time course analysis of IL-23R expression in IL-1b/IL-23
polarized Th17 cells was performed at d6 and 13 of culture by
flow cytometry. Percentage of IL-23R+Th17 cells (E) and IL-23R
MFI (F) did not differ between G (green boxes) and A (red boxes)
group neither at d6 nor at d13. Box and whiskers of 5 donors per
group are shown. Horizontal bars represent means (A) or medians
(B, C, D, E, F). Unpaired t test (A) or Mann Whitney test (B, C, D,
E, F) were performed yielding P values .0.05 for all panels.
(TIF)
Figure S3 Effect of IL23R R381Q gene variant on IL-23R
expression, IL-6-induced STAT-3 phosphorylation and
production of pro-inflammatory cytokines. Time course
analysis of IL-23R expression in IL-1b polarized Th17 cells was
performed at d 6 and d13 of culture by flow cytometry. % of IL-
23R+Th17 cells (A) and IL-23R MFI (B) did not differ between G
(green boxes) and A (red boxes) group neither at d6 nor at d13. IL-
1b-polarized Th17 cells were stimulated with IL-23 on day 13 of
culture and IL-23R mRNA was measured on d14. IL-23R mRNA
expression (C) in response to IL-23 stimulation (10 ng/ml) did not
differ in IL-1b-polarized Th17 cells from A (red dots) versus G
(green dots) group. mRNA were measured by qPCR and data are
expressed as fold increase compared to un-stimulated cells. IL-1b-
polarized Th17 cells were stimulated with IL-6 (100 ng/ml) for
15 min on d13 of culture and pSTAT-3 was measured by flow
cytometry. (D) Representative flow cytometry histograms from two
G (green frame) and two A (red frame) donors showing pSTAT-3
in response to IL-6 (pink line) as compared to unstimulated control
cells (black line) and expressed as fold Median fluorescence
Intensity (MFI). (E)Th17 cells from group G and group A did not
differ in IL-6-induced pSTAT3. IL-1b-polarized Th17 cells were
stimulated with IL-23 on d13 of culture and Th17 cytokine
mRNA and proteins were measured on d14 or d15, respectively.
IL-17F (F) and IL-26 (G) mRNA expression, as well as net IL-22
(H) and IFN-c (I) production in response to IL-23 stimulation was
not affected in IL-1b-polarized Th17 cells from A compared to G
group. IL-17F and IL-26 mRNA were measured by qPCR and
data are expressed as fold increase compared to unstimulated cells.
For panels A, B and E box and whiskers of 4–5 donors per group
are shown. In panels C, F-I each symbol corresponds to a value
obtained from an individual. Horizontal bars represent medians
(C, F, H, I) or means (G). Mann Whitney (C, F, H, I) or unpaired t
test (G) was performed yielding P values .0.05 for all panels.
(TIF)
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